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Summary  
In 2006 there were 60,000 new cases of cutaneous melanoma in the European Union and 
13,000 deaths (www.europeancancerleagues.org).  Currently available systemic treatment 
options for metastatic melanoma, including both cytotoxic and immunologic therapies, 
produce low rates of response and have modest survival impact.  Therefore, there is an urgent 
need for effective novel therapies. Molecularly targeted treatments have demonstrated 
efficacy in certain cancers e.g. in HER2-positive breast cancer and in chronic myeloid 
leukaemia.   
 
Several pathways are currently being investigated as potential molecular targets in melanoma. 
The best studied is BRAF which is frequently mutated in melanoma. A multi tyrosine kinase 
inhibitor, sorafenib, which targets BRAF, has shown promising activity in preclinical studies 
and is currently being tested in combination with chemotherapy in patients with metastatic 
disease.   
 
In addition to BRAF, therapies which target other components of the Raf/Ras/MAPK 
pathway are being investigated. Other novel targets currently being investigated include the 
PI3/AKT pathway, tyrosine kinases, angiogenesis, poly (ADP ribose) polymerases, survivin 
and heat shock protein 90. Progress on preclinical and clinical evaluation of these novel 
targets in melanoma will be reviewed. 
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 Introduction 
The incidence of melanoma has been increasing continuously over the last four decades, with 
current incidence rates varying between 15-60 per 100,000 [1]. Early-stage melanoma is 
potentially curable with wide local excision, however, for patients who develop disseminated 
disease the 5-year survival rate is less than 10% [2]. This poor prognosis is due both to the 
aggressiveness of malignant melanoma and the inherent resistance of the disease to 
conventional cytotoxic agents. The standard chemotherapy treatments, single-agent 
dacarbazine, or temozolomide, produce low response rates of 15-20% [3]. Combinations of 
dacarbazine or temozolomide with other cytotoxic therapies have not significantly improved 
patient survival [2]. Adjuvant immunotherapy with interferon alpha offers some benefit in 
terms of recurrence-free and overall survival. Adding immunomodulators (e.g. interferon 
alpha or interleukin-2) to chemotherapy increases the response rates (and the toxicity) in 
patients with metastatic disease, but has not been shown to produce superior survival 
compared to chemotherapy alone in random assignment trials [4]. There is therefore an 
urgent need for new systemic therapies for metastatic melanoma.  
 
Our increasing knowledge of the molecular alterations associated with melanoma progression 
provides potential druggable targets for development of novel therapeutic strategies, 
including alterations in key intracellular signalling pathways and growth factor receptors. 
 
While several new molecular immunotherapy approaches are being explored [5], the focus of 
this review is on novel non-immunologic molecularly targeted therapies for melanoma. 
 
Targeting the Ras/Raf/MAPK pathway in melanoma 
 4
Activation of the Ras/Raf/MAPK pathway is a frequent and early event in melanoma [6].  
BRAF, a key component in the pathway, is mutated in 60-70 % of melanoma cases [7].  The 
mutation valine-600-glutamic acid (V600E) accounts for approximately 80 % of BRAF 
mutations [8]. Analysis of BRAF mutation status showed that the presence of the mutated 
BRAF in primary tumours (n=114) did not impact on prognosis or survival but was 
associated with a significantly poorer prognosis (n=86) when detected in metastatic 
melanomas [9]. 
  
A number of BRAF inhibitors are in clinical development (Table 1).  Sorafenib (BAY43-
9006, Bayer) is a bi-aryl urea small molecule inhibitor of vascular endothelial growth factor 
receptor (VEGFR) and Raf kinase, which also has activity against C-Kit and platelet-derived 
growth factor receptor beta (PDGFR-Preclinical studies demonstrated that sorafenib can 
inhibit BRAF in melanoma cell lines resulting in inhibition of MAPK activity and melanoma 
cell growth in vitro and in vivo [10]. Sorafenib also exerts antiangiogenic effects by blocking 
Ras/Raf/MAPK signalling in endothelial cells [11]. Sorafenib showed no significant 
antitumour activity as a single agent in advanced melanoma [12], however, in a recent 
randomised phase II study, sorafenib in combination with dacarbazine produced significantly 
improved progression free survival (21.1 weeks vs. 11.7 weeks, hazard ratio [HR], 0.619) 
compared to dacarbazine alone. There was no improvement in overall survival [13]. The 
addition of sorafenib to paclitaxel and carboplatin as second line treatment for advanced 
melanoma did not improve progression-free survival or overall response rates [14]. This 
regimen is currently being evaluated in a phase III trial in chemotherapy-naïve advanced 
melanoma. Several phase II trials of sorafenib in combination with chemotherapy or with 
other targeted agents are currently ongoing (www.clinicaltrials.gov). 
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Two specific mutant BRAF inhibitors, PLX-4032 and PLX-4720 (Plexxikon Inc.) have been 
developed and are being tested in melanoma.  PLX-4720, a 7-azaindole derivative, reduced 
MAPK activation in V600E mutated melanoma cell lines but did not alter MAPK activation 
in BRAF wild type cell lines, suggesting that PLX-4720 has the ability to specifically target 
cancer cells with mutant BRAF.  In vivo studies confirmed the inhibition of melanoma cell 
growth and no toxicity was reported [15]. RAF-265 (Novartis) is a potent inhibitor of Raf and 
VEGFR. Preclinical research has shown that RAF-265 inhibits all 3 isoforms of Raf, as well 
as mutant B-Raf (www.novartisoncology.com). Both PLX-4032 and RAF-265 are currently 
recruiting patients for phase I trials in metastatic melanoma.  
 
MEK (MAPK/ERK kinase), downstream of BRAF may be a potential target in melanoma. 
BRAF-induced hyperactivation of MEK has been implicated in melanoma [16].  A number of 
MEK inhibitors are being investigated in solid tumours, including RO5126766 (Hoffman-La 
Roche), and AZD6244 (AstraZeneca) which has been shown to be cytostatic as monotherapy 
and cytotoxic in combination with docetaxel in preclinical evaluation in melanoma [6]. 
AZD6244 is currently undergoing evaluation in phase I-II trials in melanoma. 
 
 Targeting the PI3/AKT pathway in melanoma 
Constitutive activation of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway (Figure 1) 
has been implicated in chemoresistance in many human cancers, including melanoma [17]. 
Although PI3K itself is rarely mutated [18] or overexpressed [19] in melanoma, activation of 
downstream signalling components, e.g. AKT, have been implicated in melanoma 
progression [20]. In one study, phosphorylated AKT was detected in 17, 43, 49, and 77% of 
normal nevi (n=12), dysplastic nevi (n=58), primary melanoma (n=170) and melanoma 
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metastases (n=52), and strong p-AKT staining correlated inversely with overall and 5-year 
survival of patients with primary melanoma (p < 0.05) [21].   
 
Increased AKT activation can be caused by mutation or loss of phosphatase and tensin 
homolog (PTEN), a tumour suppressor which can downregulate the AKT pathway [22]. Loss 
of PTEN reduces apoptosis and promotes cell survival and thereby promotes melanoma 
tumour development, and has been reported in 20-40% of melanomas [23,24]. Increased 
mTOR (mammalian target of rapamycin) activation has also been implicated in melanoma 
cell growth. Proliferation of melanoma cells lines was blocked by the mTOR inhibitor 
rapamycin [25]. mTOR is a downstream target of the PI3K/AKT kinase signalling pathway 
and regulates cancer cell growth and metabolism [26,27]. 
 
Rapamycin (sirolimus) and its analogs, temsirolimus (CCI-779, Wyeth Pharmaceuticals), 
everolimus (RAD-001, Novartis) and deforolimus (AP23573, ARIAD Pharmaceuticals, Inc. 
and Merck & Co., Inc.), which inhibit mTOR have shown promising activity in several 
cancers [28]. Rapamycin has been shown to inhibit melanoma cell growth in vitro and in 
vivo, and synergistically enhances apoptosis and chemosensitivity in melanoma cells [29-32].  
Temsirolimus also inhibits growth and enhances response to dacarbazine and cisplatin in 
melanoma cell lines and mouse models of melanoma [33]. Temsirolimus did not demonstrate 
any clinical benefit as a single agent in the treatment of metastatic melanoma [34].  Phase II 
trials of temsirolimus and everolimus in combination with chemotherapy or other targeted 
agents in melanoma, are currently recruiting patients (www.clinicaltrials.gov).   
 
The pan-PI3K inhibitor, LY294002, which has been restricted to preclinical studies , showed 
antitumour activity in preclinical models of melanoma [35,36], demonstrating the potential 
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benefits of targeting the PI3K/AKT pathway in melanoma. Although specific PI3K inhibitors 
have not yet been tested in melanoma patients, a number of inhibitors are undergoing trials in 
other solid tumours and may be potential therapies for melanoma.  For example NVP-BEZ 
235, a dual PI3K/mTOR inhibitor, has shown antiproliferative effects in glioblastoma, 
multiple myeloma and breast cancer cell lines [37-39], and is currently in phase I/II trials in 
solid tumours and breast cancer (www.clinicaltrials.gov). Several other PI3K inhibitors are 
also in phase I trials, including SF1126 (Semofore), XL765 and XL147 (Exelixis Inc.) and 
GDC-0941 (Genentech). 
 
Perifosine (AOI Pharma Inc. and Keryx Biopharmaceuticals), an alkylphosphocholine (APC) 
analogue, inhibits phosphorylation of AKT by blocking membrane translocation [28]. A 
phase II trial of single-agent perifosine as first line treatment in metastatic melanoma patients 
produced no objective responses [40]. Further trials of perifosine in combination with 
chemotherapy and targeted agents in other solid tumours are ongoing.  
 
Targeting either the MAPK or AKT pathway individually may be beneficial, but there is 
substantial preclinical evidence to support targeting both pathways simultaneously [32,41].  
Indeed, Cheung et al. showed that AKT3 and mutant BRAF cooperate to promote melanoma 
development [15]. Dual inhibition of MAPK and PI3K/AKT/mTOR has shown antitumour 
activity in melanoma cell lines [32,41,42]. The combination of MAPK and AKT inhibitors 
completely suppressed invasive growth of melanoma cells in regenerated human skin [43]. A 
phase I/II trial of combined BRAF and mTOR inhibition by sorafenib and temsirolimus, is 
currently recruiting melanoma patients (www.clinicaltrials.gov). 
 
Novel tyrosine kinase targets in melanoma 
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C-Kit receptor 
Stimulation of the C-Kit receptor tyrosine kinase by its ligand, stem cell factor (SCF), leads 
to activation of intracellular signalling pathways including Ras/Raf/MAPK, SRC and 
PI3K/AKT signalling [44].  It is expressed at high levels in normal melanocytes [45] and is 
essential for normal melanocyte development and homeostasis [46]. Until recently it was 
believed that c-Kit expression was lost with melanoma progression [47].  However, recent 
studies have shown that c-Kit is overexpressed in a small percentage of melanoma patients 
[45,48-50]. The c-Kit overexpressing patients are generally not BRAF-mutated and are 
defined as being mucosal, acral or chronic sun damaged [51-53].     
 
Imatinib mesylate (Gleevec, Novartis), which targets c-Kit in addition to BCR-Abl, inhibited 
proliferation in melanoma cell lines due to cell cycle arrest in the G2M phase [54].  Imatinib 
has been tested in phase II trials in metastatic melanoma patients without success [55].  
However, trials which target acral melanoma patients who have c-Kit over expression, 
exclusive of BRAF mutation, are underway [52].   
 
 SRC kinase 
Members of the SRC kinase family have been implicated in melanoma progression [56-60] 
and both SRC and Yes are reported to be elevated in melanoma cells compared to normal 
melanocytes [56,61]. The many functions of SRC kinase may be attributable to its 
relationships with several oncogenes such as the non receptor tyrosine kinase, focal adhesion 
kinase (FAK) and Stat3 [62]. SRC kinase regulates Stat3 which is active in melanoma but not 
normal or benign melanocytes [63]. Blocking SRC kinase leads to inhibition of Stat3, and as 
a result, induction of apoptosis in melanoma cells [64].  
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Dasatinib, a multitarget tyrosine kinase inhibitor, which targets BCR-Abl, SRC kinases, C-
Kit, PDGFR and ephrin-A receptor kinases, is the most potent SRC kinase inhibitor currently 
in clinical development with an IC50 of 0.5 nM for SRC kinase (IC50 of < 30 nM for the other 
targets) [65]. In melanoma cell lines, dasatinib has shown antiproliferative effects and 
significantly reduced tumour cell migration and invasion [66]. Dasatinib has also shown 
preclinical activity in prostate cancer [67], triple-negative breast cancer [68] and colon cancer 
cells [69]. Dasatinib is currently being tested in phase I and II trials in metastatic melanoma. 
 
AZD0530 (AstraZeneca), a selective SRC kinase inhibitor, reduced tumour formation in a 
skin carcinogenesis model [69], and reduced tumour growth in a SRC-transfected 3T3-
fibroblast xenograft model [70].  A phase II clinical trial of AZD0530, as a single agent, is 
currently recruiting patients with stage III/IV melanoma.  SKI-606, a SRC/Abl kinase 
inhibitor has shown antitumour effects in breast cancer in vitro and in vivo [71], but has not 
yet been tested in melanoma. 
 
 c-Met 
The c-Met receptor tyrosine kinase is involved in cell growth, invasion, metastasis, and 
angiogenesis. Binding of its ligand, hepatocyte growth factor (HGF), to c-Met results in 
activation of c-Met and subsequent activation of signal transducers such as PI-3-kinase, PLC-
γ, STATs, ERK 1 and 2, and FAK [72]. Through increased paracrine or autocrine signalling, 
this pathway can enhance tumour cell proliferation, survival, motility, and invasion [73] and 
is implicated in a variety of human malignancies including melanoma. c-Met is 
overexpressed and associated with the metastatic potential of melanoma and patient survival 
[74-77]. 
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c-Met is expressed on normal epithelial cells and melanocytes. HGF is normally produced 
mainly by mesenchymal cells and interacts with its receptor in a paracrine manner [78]. Most 
melanoma cells, but not normal melanocytes, produce HGF, which can induce sustained 
activation of its receptor. Also, prolonged HGF stimulation induces downregulation of the 
intracellular adhesive molecule E-cadherin that is implicated in the control of melanocyte 
proliferation [79]. In transgenic mice that ubiquitously expressed HGF, ectopic localisation of 
melanocytes and hyperpigmentation in skin were observed, melanoma arose spontaneously 
and UV radiation-induced carcinogensis was accelerated [80]. Hence, an autocrine HGF/c-
Met signalling loop may be involved in the development of melanomas [81]. 
 
Puri et al. [81] showed that a small molecule tyrosine kinase inhibitor of c-Met, SU11274, 
inhibited growth of melanoma cells by causing apoptosis and inducing differentiation. c-Met 
was detected in 88% of melanomas (n=40) and in only 15% of nevi (n=20) examined.  
Mutations in the juxtamembrane domain of c-Met were also identified in melanoma cell lines 
and in tumour tissue [81].  
 
Thus the c-Met/HGF pathway may be a rational target for therapeutic intervention in 
melanoma. Several c-Met and HGF inhibitors are in phase I clinical trials at present and the 
dual c-Met/VEGFR inhibitor, GSK1363089 (GlaxoSmithKline and Exelexis) is being tested 
in phase II trials in a number of solid tumours.   
 
Targeting angiogenesis in melanoma 
Similar to other cancers, angiogenesis is a critical step in the development of melanoma [for 
review see 82]. Melanoma cells produce several proangiogenic factors, including vascular 
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endothelial growth factor (VEGF), platelet derived growth factor (PDGF), basic fibroblast 
growth factor (bFGF) and interleukin 8. In addition to targeting BRAF, sorafenib targets the 
VEGF and PDGF receptors on endothelial cells, and has demonstrated antiangiogenic activity 
in tumour xenograft models [83,94]. Several other antiangiogenic therapies are being tested 
in melanoma including the VEGF monoclonal antibody bevacizumab (Avastin, Hoffman-La 
Roche) and the small molecule inhibitors sunitinib (Sutent, Pfizer), axitinib (AG 013736, 
Pfizer) and cediranib (AZD2171, AstraZeneca). A phase II trial of carboplatin, paclitaxel, and 
bevacizumab recently reported clinical benefit in patients with unresectable stage IV 
melanoma [85]. Nine out of 53 patients (17%) achieved partial remission, and 30 (57%) 
achieved stable disease for at least 8 weeks. Median progression-free survival and median 
overall survival were 6 and 12 months, respectively. Axitinib, which targets VEGF receptors 
and FGF receptor [86,87], has demonstrated single-agent activity in patients with metastatic 
melanoma, with an overall response rate of 15.6% [88].  
 
Other potential targets in melanoma 
Poly (ADP ribose) polymerases (PARP) 
Poly (ADP ribose) polymerases (PARP) are a family of 17 members which are found in 
nearly all eukaryotic cells [89]  and act as DNA nick sensors which can signal the presence of 
DNA damage, e.g. caused by methylating agents, and facilitate its repair [90,91] . PARP 
inhibitors have been developed to potentiate the effect of DNA damaging agents, such as 
temozolomide and dacarbazine [92]. In melanoma, overexpression of PARP in radial and 
vertical growth phase has been associated with recurrence [93]. 
In preclinical studies, systemic administration of a PARP inhibitor GPI-15427 (Guilford 
Pharmaceutical Inc.) potentiated temozolomide activity in an intracranial melanoma model 
[94]. ABT-888 (Abbott), a PARP-1/PARP-2 inhibitor, also potentiates temozolomide activity 
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[95] and achieved a reduction in PARP-1 levels in patients, including one melanoma patient 
[96]. Preliminary data from a phase I trial of the PARP inhibitor INO-1001 (Inotek 
Pharmaceuticals), an isoindolinone derivative, in combination with temozolomide in patients 
with stage IV unresectable melanoma, reported that of the 3 evaluable patients, one had an 
objective response, one had stable disease, and the third patient had progressed [97].   
As most chemotherapy agents are used at the maximum tolerated dose, it is unclear whether 
combination of PARP inhibitors and chemotherapy will exacerbate the dose-limiting effects 
of chemotherapy [98].  Despite these concerns, PARP inhibitors are currently one of the most 
promising therapeutic strategies for melanoma.   
 
Survivin 
Apoptosis or programmed cell death is commonly dysregulated in cancer [99], including 
melanoma [100]. Survivin, a member of the inhibitor of apoptosis (IAP) family, has been 
implicated in inhibition of apoptosis and regulation of cell division [101]. Expression of 
survivin in tumours is associated with increased aggressiveness and decreased survival 
[102,103] and several studies have identified high levels of survivin expression in metastatic 
melanoma [103-105]. Interestingly, the localisation of survivin alters as melanoma 
progresses. Survivin expression has been identified in the cytoplasm in a spectrum of 
melanocytic lesions, however in metastatic melanoma its localisation changes to the nucleus 
[106], suggesting that nuclear survivin may be associated with poor prognosis. Studies in 
other solid tumours have also reported an association between nuclear survivin and poor 
prognosis [107,108].Grossman et al. showed that targeting survivin in melanoma cells 
resulted in increased apoptosis [105].  
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Several novel molecules have been developed which can suppress the activity of survivin 
(Table 1). The small molecule survivin inhibitor, YM155, targets survivin and induces 
apoptosis in prostate cancer cell lines.  In xenograft studies YM155 induced significant 
tumour regression.  Interestingly, the tumour concentration of YM155 has been found to be 
20 times greater than the plasma concentration, demonstrating the cancer-specific nature of 
this compound [109].  A phase II trial of YM155 in metastatic melanoma demonstrated that 
the drug was well tolerated and one patient out of the 34 treated had an objective response 
and a second patient a minor response [110].  The first survivin antisense molecule, 
LY2181308 (Lilly and Co., and ISIS Pharmaceuticals) is currently in phase II trials in a 
number of solid tumours. A novel antisense molecule, SPC3042 (Santaris Pharma), which is 
a 16-mer locked nucleic acid oligonucleotide, has an IC50 < 5 nM for downregulation of 
survivin mRNA and protein. SPC3042 induces cell cycle arrest and apoptosis in vitro and 
also sensitised prostate cancer cells to paclitaxel treatment [111].   
 
Heat shock protein 90  
Heat shock protein 90 (HSP90) is an essential molecular chaperone that regulates the 
stabilisation, activation, and degradation of client proteins [112], such as BCR-ABL, EGFR, 
CRAF, BRAF, VEGFR, and MET [113]. Inhibition of HSP90 leads to targeted degradation 
of the client proteins by the proteasome, resulting in inhibition of growth and induction of 
apoptosis [112,114].  
 
Mutated BRAF (V600E) is a client protein of HSP90, and HSP90 inhibition results in 
preferentially degradation of mutant BRAF over wild-type BRAF [115,116].  Furthermore, in 
a recent tissue microarray study, HSP90 expression was significantly higher in melanomas 
(n=468) than in nevi (n=414) and in metastatic (n=270) vs. primary specimens (n=198). In 
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primary melanomas, high HSP90 expression was associated with the adverse histologic 
features of a higher Clark level and increased Breslow depth [117]. Thus, HSP90 may be a 
good target for melanoma treatment. 
 
Several HSP90 inhibitors are in preclinical or clinical development. Early attempts focussed 
on geldanamycin and radicicol analogues but more recent compounds being studied include 
synthetic small molecule inhibitors such as AUY922 (Novartis), BIIB021 (Conforma 
Therapeutics), and SNX2112 (Serenex Inc.) [113]. 
 
A phase I study of tanespimycin (17-allylamino, 17-demethoxygeldanamycin (17-AAG)) 
(Kosan Biosciences Inc.), a geldanamycin derivative, in patients with advanced malignancies 
included 6 patients with metastatic malignant melanoma. No patient had a complete or partial 
response. Four of the melanoma patients progressed within 2 months, while 2 melanoma 
patients had prolonged stable disease at 15 and 49 months [118]. The patient who had stable 
disease at 15 months had a (V600E)BRAF mutation and wild-type NRAS, while the patient 
who had stable disease at 49 months had a (G13D)NRAS mutation and wild-type BRAF, 
suggesting that mutations in BRAF or NRAS may be predictive of response to HSP90 
inhibition in melanoma [119]. However, a recently published phase II trial of 17-AAG in 
patients with metastatic melanoma was disappointing as no objective antimelanoma response 
was seen. Although an increase in HSP70 and a decrease in cyclin D1 were observed post-
treatment, RAF levels were not altered. The authors concluded that further trials in melanoma 
should focus on a more potent HSP90 inhibitor or a formulation that can be administered 
chronically for a more prolonged suppression of the MAPK pathway [120].  
 
Conclusions 
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At this point in time no non-immunologic molecular targeted treatment can be considered as 
standard therapy for metastatic melanoma. Several agents have shown promising preliminary 
activity. The very poor results which are obtained with conventional chemotherapy and 
immunotherapy provide a powerful ethical justification for studying candidate molecular 
agents in the first-line therapy of appropriately selected patients with metastatic disease.  
 
One of the challenges of molecular therapeutics is the development of appropriate drug 
development processes for novel agents. The methodologies used in the development of 
conventional cytotoxics, for example large-scale sequential safety and efficacy studies 
conducted in patients with histologically determined eligibility criteria, may not be optimal. 
Many molecular agents have produced very modest results in trials of this type conducted in 
other solid tumours. Molecular eligibility, as used in the development of trastuzumab, has 
resulted in a greater impact. Thus, every effort should be made to ensure that all therapeutic 
trials of novel molecular agents in melanoma and other cancers have mandatory tissue 
collection and translational components. 
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     Table 1. Molecularly targeted agents currently being evaluated in malignant melanoma 
Drug name Targets 
Clinical trials  
statusa 
Sorafenib B-Raf, VEGF, PDGFR, c-Kit, Phase III 
RAF-265 Raf, VEGFR Phase I 
PLX-4032 Mutant B-Raf Phase I 
RO5126766 MEK Phase I/II 
Perifosine AKT Phase II 
Rapamycin mTOR Phase II 
Temsirolimus mTOR Phase II 
Everolimus mTOR Phase II 
Deforolimus mTOR Phase I 
Imatinib mesylate c-Kit, BCR-Abl, PDGFR Phase II 
Bevacizumab VEGF Phase II 
Sunitinib VEGFR, PDGFR, c-Kit, FLT3, CSF-1R,  RET Phase II 
Axitinib VEGFR, PDGFR  Phase II 
Cediranib VEGFR, PDGFR, FGFR, c-Kit Phase II 
KU-0059436 PARP Phase I 
ABT-888 PARP Phase I 
INO-1001 PARP Phase I 
Dasatinib BCR-Abl, Src, c-KIT, PDGFR, Ephrin-A receptors Phase I/II 
AZD0530 Src, Abl Phase II 
YM-115 Survivin Phase II 
LY2181308 Survivin Phase II 
17-AAG HSP90 Phase II 
a Clinical trial status obtained from www.clinicaltrials.gov. 
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Figure 1. Signalling pathways and molecules that are potential targets for melanoma therapy.
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